Peptide Therapeutics in Metabolic Disorders Market Analysis By 2025
Request for Sample Copy of Research Report@
Manufacturers are focusing on developments in biologics and biopharmaceutical peptides and proteins for application in diagnostics and therapies. According to the data published in Drug Discovery Today, in January 2015, around 140 peptide therapeutics are currently evaluated in clinical trials. Peptide therapeutics are increasingly been used for therapeutics in metabolic diseases and oncology. Rising incidence of metabolic diseases such as Diabetes mellitus type 2 (T2DM) and Obesity are expected to be factors driving growth of the market. According to World Health Organization (WHO) 2017 data findings, the number people suffering from diabetes have increased from 108 million to 422 million in 2014. Similarly, the world obesity rate has increased three times since 1975 and in 2016, over 1.9 billion adults (18 year and above) were estimated to be overweight. Moreover, high incidence rate of metabolic disorders is expected to propel growth of peptide therapeutics in metabolic disorders market in the near future. According to the Centers for Disease Control and Prevention (CDC) October 2017 data findings, in 2011–2012, 78 million U.S. adults had low-density lipoprotein cholesterol levels, which put them at high risk of heart disease and stroke. However, high prices of products is expected to negatively impact the overall market growth.
Among the metabolic disorders, the risk of developing type 1 and type 2 diabetes is related to the combination of variants in multiple genes. In rare cases, patients which are monogenic having single gene mutation which can lead to diabetes. The first peptide to be administrated therapeutically was insulin and has been used in the treatment of diabetes. Development of novel analogues such as lispro insulin that is an injection to be taken prior to meal, has also aided in growth of the market. Another important peptide is glucagon like peptide-1 (GLP-1), which has insulin-releasing properties and also helps to suppress the glucagon level. The glucose dependent action of GLP-1 is more potent to regulate glucose level after a meal. These properties of peptides has aided in development of novel therapeutics and is expected to drive growth of the market in the near future. According to the data published in the January 2015, in Drug Discovery Today Journal, total 60 peptides-based drugs such as viscozyme, pulmozyme, glucagen are available in the market and number of other therapeutic peptides such as cpd86 (preclinical), MOD-6030 (preclinical), MAR709 (II) and semaglutide (III) are currently evaluated in different phase of clinical trial thus, strong pipeline is expected to propel growth of the peptide therapeutics in metabolic disorders market in the near future.
Collaborations and new product launches:
Key players in the market are focusing on collaborations and new product launches, in order to enhance their market share. For instance, Rhythm Pharmaceuticals Inc. is engaged in developing obesity drug called setmelanotide a Melanocortin 4 receptor (MC4R) agonist peptide that is meant to be injected daily to regulate the body energy balance and appetite. Moreover, in June 2017, Rhythm Pharmaceuticals and Camurus AB released the positive initial results from ongoing Phase 1A clinical trial, which evaluated the pharmacokinetics and tolerability of an extended-release formulation of setmelanotide. The company is also conducting trials for the treatment of extremely rare metabolic disorders such as Pro-opiomelanocortin (POMC) and Leptin receptor (LepR) deficiency obesity. Furthermore, in September, 2017, Zealand Pharma and Torrey Pines Institute for Molecular Studies entered into a research collaboration for multi-target research to identify novel peptide-based products by using Torrey Pines Institute for Molecular Studies (TPIMS’s) peptide libraries. This collaboration will help to develop specialty medicines to treat metabolic and gastrointestinal diseases.
Key players in the Peptide Therapeutics in Metabolic Disorders Market:
Some of the key players operating in the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S.
Request for Discount Before Buying This Business Reports @ www.coherentmarketinsights.com/insight/request-discount/2003
Global Peptide Therapeutics in Metabolic Disorders Market Taxonomy
On the basis of route of administration, peptide therapeutics in metabolic disorders market is segmented into:
On the basis of synthesis technology, peptide therapeutics in metabolic disorders market is segmented into:
Solid Phase Peptide Synthesis
Liquid Phase Peptide Synthesis
On the basis of distribution channels, peptide therapeutics in metabolic disorders market is segmented into:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peptide Therapeutics in Metabolic Disorders Market Analysis By 2025 here
News-ID: 1186019 • Views: 144
More Releases from Coherent Market Insights - Pharmaceutical Industry
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around
Global Opioids Agonist Drugs Market Is Recurring & Impressive Growth Generating …
Opioid drugs act on the opioid receptors present in the central and peripheral nervous system. The drug class primarily used in relieving pain includes natural, semi-synthetic, and synthetic opioids. Codeine, morphine, hydrocodone, oxycodone, heroin, and fentanyl are some of the major prescription drugs in the global opioids agonist drugs market. Opioids can be administered as oral pills, parenteral, liquids, patches, or lozenges. Overdose and drug abuse is a major concern
Pediatric Nutrition Market is Booming 2019 by Top Key Players Reckitt Benckiser …
Pediatric nutrition is an important source of nutritional supplement for babies during their formative years. These products are available in milk-based, Soy-based, amino acid-based, and organic forms. These nutritional products support brain development and also helps in the management of allergies and metabolic disorder. Highest number of births are recorded in Asia Pacific, and hence, the region holds maximum opportunity for market players. Lactose intolerance, allergy to cow’s protein milk,
Dravet Syndrome Treatment Market: Business Planning Research, Reviews & Comparis …
Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic seizures, absence seizures, atypical absence seizures, atonic seizures, focal aware or impaired awareness seizures (previously
More Releases for Peptide
Peptide Therapeutics Market | Forecast up to 2024
Global Peptide Therapeutics Market: Overview This report provides in-depth region wise and country wise analysis of the peptide therapeutics market. Stakeholders of this report include manufacturers of peptide products, raw material suppliers, nutraceutical and cosmeceutical companies, food processing industries and new players planning to enter the market. It further provides qualitative and quantitative analysis of the global peptide therapeutics market. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market
Peptide Vaccine Market Peptide Vaccine Clinical Pipeline Report 2020
For Report Sample Contact: firstname.lastname@example.org or +91-11-47067990 Report Table of Contents 1. Peptide Vaccine: A Prologue to Sub-Unit Vaccines 1.1 Introduction 1.2 Glimpse of Antiquity 2. Need of Peptide Vaccines 2.1 Why Peptides – More Desirable 2.2 Peptide Vaccines V/S Traditional Vaccines 3. Classification of Peptide Vaccines 3.1 On the Basis of Sources Obtained 3.2 On the Basis of Length 3.3 On the Basis of
Global Natriuretic Peptide Market Research Report 2017
Report Hive Market Research Released a New Research Report of 107 pages on Title " Global Natriuretic Peptide Market Research Report 2017 "with detailed Analysis, Forecast and Strategies. In this report, the global Natriuretic Peptide market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented
Global Peptide Therapeutics Pipeline Insight 2015
Peptides are small molecules of varying molecular masses that consist of amino acids joined with the help of peptide bonds (CONH2). One end of the molecule consists of carboxyl (COOH2) group while the other end has amino (NH2) group giving rise to polarity. Biologically, they are very important and found to play an important role in various anabolic and catabolic processes. They are essential component of cell signaling pathways, immune
Global Peptide Vaccine Market & Pipeline Insight
Peptide vaccines are peptides that exhibit pharmacological properties by activating human immune system rather than showing pharmacologically activity by themselves. They are administered into body to enter in lymph nodes where they induce long lasting immune response. They utilize immune system and develop long term acquired immunity which has capability to prevent future incidences of pathogen attack. Every living cell in human body has surface markers as an instrument to
Animal Antibacterial Peptide 2024 Market Research Report
Peptides are derived from animal source and possess antibacterial activity that comes under animal antibacterial peptides. They contain residue of amino acids generally about 15 to 45. Antibacterial peptides are the effector molecules of innate immunity. Majority of the antibacterial peptides are cationic in nature. In insects, the cecropin type of linear peptide without cysteine are found. Now, more than 900 sequences of proteins and antibacterial peptides from plants and